羟基红花黄色素A联合黄芪甲苷对慢性肾脏病的保护作用

Protective Effect of Hydroxysafflor Yellow A Combined with Astragaloside Ⅳ on Chronic Kidney Disease

  • 摘要: 目的 观察羟基红花黄色素A联合黄芪甲苷对大鼠慢性肾病的防治作用,并探讨其机制。方法 采用大鼠5/6肾切除模型,将36只雄性SD大鼠随机分为假手术组、模型组、治疗组,连续给药1周,1月后处死大鼠,测定各组大鼠治疗前及治疗后血清中血肌酐(Scr)和尿素氮(BUN)水平;检测SOD、MDA水平以示氧化应激变化;采用HE染色观察各组小鼠肾脏组织病理变化;采用Western blot法检测各组小鼠肾脏组织中的SIRT1、eNOS和PGC-1α蛋白。结果 与模型组相比,治疗组降低了SCr和BUN水平,改善了肾组织病理学变化,显著降低肾脏氧化应激水平,同时提高了SIRT1、eNOS和PGC-1α蛋白的表达。结论 羟基红花黄色素A(HSYA)联合黄芪甲苷(As-Ⅳ)可能通过SIRT1/eNOS/PGC-1α通路以及氧化应激,从而发挥抗慢性肾脏病的作用。

     

    Abstract: OBJECTIVE To observe the preventive and therapeutic effects of hydroxysafflor yellow A combined with astragaloside Ⅳ on chronic kidney disease in rats and to explore its mechanism. METHODS 36 male Sprague-Dawley rats were randomly divided into sham operation group, model group and treatment group (HSYA+As-Ⅳ) by rat 5/6 nephrectomy model. One week after continuous administration, rats were sacrificed one month later. Serum levels of serum creatinine (Scr) and urea nitrogen (BUN) were measured before and after treatment in each group. The levels of SOD and MDA were measured to show oxidative stress changes. HE staining was used to observe the small groups. Histopathological changes in rat kidney, Western blot was used to detect SIRT1, eNOS and PGC-1α protein in kidney tissues of mice. RESULTS Compared with the model group, the treatment group reduced the levels of increased SCr and BUN, improved renal pathological changes, significantly reduced renal oxidative stress, and increased the expression of SIRT1, eNOS and PGC-1α proteins. CONCLUSION HSYA combined with As-Ⅳ may exert anti-chronic kidney disease through SIRT1/eNOS/PGC-1α pathway and oxidative stress.

     

/

返回文章
返回